When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate receptor alpha (FRα), top-line data from a Phase 1b/2 trial shows. The trial findings were presented in “Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer,” an oral presentation given recently at the…
You must be logged in to read/download the full post.
The post Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses appeared first on BioNewsFeeds.